Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Heterozygous variants in the NBS1 gene (HGNC:7652) have been implicated as moderate-penetrance risk factors for hereditary breast carcinoma (MONDO:0016419). Nibrin, the protein encoded by NBS1, forms the MRN complex with MRE11 and RAD50, essential for DNA double-strand break recognition and repair.
In a Northern Finnish case-control cohort of 317 newly diagnosed hereditary breast cancer patients versus 1,000 matched healthy controls, the NBS1 c.448C>T (p.Leu150Phe) missense variant was identified in two unrelated probands and absent from controls (P = 0.0004) (PMID:16474176). This variant affects a conserved residue within the BRCT domain and suggests a founder effect in this population.
No familial segregation studies have been reported for c.448C>T, and no affected relatives with confirmed variant segregation have been described, yielding limited case-level evidence for pathogenicity of this allele.
Functional studies of NBS1 support a haploinsufficiency mechanism: Nbn knockout in mice is embryonic lethal, whereas hypomorphic alleles produce truncated proteins that partially rescue viability but compromise genomic stability, radiosensitivity, and cell viability (PMID:15333589). Moreover, ATM-dependent phosphorylation of nibrin at Ser343 is critical for DNA damage signaling, underscoring the impact of BRCT-domain alterations on MRN complex function (PMID:10802669).
There are no reports disputing the association of NBS1 heterozygous BRCT-domain variants with hereditary breast carcinoma, although sensitivity of risk estimates to population founder effects warrants further study.
Overall, limited genetic evidence for NBS1 c.448C>T coupled with concordant functional data supports a Limited clinical validity classification. Additional segregation and replication studies are needed to advance this association. Key take-home: NBS1 heterozygous variants involving the BRCT domain confer moderate genomic instability and may inform risk assessment in hereditary breast carcinoma.
Gene–Disease AssociationLimitedCase-control study identified NBS1 c.448C>T in 2/317 probands with P = 0.0004 ([PMID:16474176]); no segregation data. Genetic EvidenceLimitedTwo unrelated probands harbor c.448C>T (p.Leu150Phe) without familial segregation. Functional EvidenceModerateMurine Nbn hypomorphic alleles and ATM-dependent phosphorylation studies demonstrate haploinsufficiency and impaired MRN complex function concordant with cancer predisposition. |